Myeloid malignancy

Details

Title

Myeloid malignancy

Type

Stage Two

Module code

HLS164

Requirement

Compulsory

Module objective

By the end of the training period trainees will, in respect of myeloid malignancy, be able to:

• analyse, synthesise, evaluate and apply knowledge
• perform, adapt and master a range of technical and clinical skills and procedures
• demonstrate the attitudes and behaviours necessary for professional practice as a consultant clinical scientist dealing with the complexities, uncertainties and tensions of professional practice at this level.

Knowledge and understanding

By the end of the training period the trainee will be able to demonstrate the ability to analyse, evaluate and synthesise relevant knowledge and its application to their professional practice in relation to

• acute myeloid leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes, myeloproliferative disorders including polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis, mastocytosis, clonal hypereosinophilic syndromes and chronic neutrophilic leukaemia
• epidemiology and pathophysiology of disease
• laboratory and clinical phenotypic diagnosis and classification
• cell surface marker analysis
• cytogenetics and molecular genetics
• minimal residual disease
• clinical aspects: therapeutic principles and measures.

Technical and clinical skills

By the end of the training period the trainee will be able to demonstrate a critical understanding of current relevant research, theory and knowledge and its application to the performance, adaptation and mastery of the following technical procedures and laboratory skills:

• be competent in the laboratory investigation, diagnosis and monitoring of patients with malignant myeloid disorders
• produce a fully interpretative clinical diagnostic laboratory report
• understand clinical management of malignant myeloid disorders.